Long-term survivors of Hodgkin lymphoma require close follow-up and early-detection strategies to mitigate the risks of late complications, particularly subsequent malignancies and cardiovascular disease.
Long-term HL survivors merit intensified surveillance for SMN and CVD; leaves open optimal risk-reduction protocols for prospective validation.
Long-term survivors of Hodgkin lymphoma (HL) are at an increased risk for a range of late complications, with subsequent malignant neoplasm and cardiovascular disease representing the 2 leading causes of death in these patients. Raising awareness, close follow-up, and adoption of selected early-detection and risk-reduction strategies may help to reduce the adverse impact of these late effects on patients. This chapter reviews known long-term complications of HL therapy, risk factors, and the timing of their occurrence. Where available, data on the efficacy of screening for selected late effects of HL are presented. Current evidence-based and consensus-based recommendations on follow-up of long-term HL survivors are also reviewed. As HL therapy evolves over time, late effects and implications on follow-up of patients treated in the contemporary era should be considered and opportunities for future research should be explored.
No takes yet. Share an insight, caveat, or question.
Andrea K. Ng (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: